Skip to main content Help with accessibility Skip to main navigation

January 2024 updates to the website

The website has now been updated following January's LSCMMG

The following guidelines have been added/updated:

High strength fluoride toothpastes position statement - added

The following medicines have been added/ updated following the Clinical Effectiveness Group (CEG) meeting:

Ranolazine - as adjunctive therapy in the treatment of stable angina in patients inadequately controlled or intolerant of first-line antianginal therapies (RAG update)

Bimekizumab - active psoriatic arthritis (NICE TA916)

Bimekizumab - axial spondyloarthritis (NICE TA918)

Rimegepant - treating migraine (NICE TA919)

Tofacitinib - active ankylosing spondylitis (NICE TA920)

Mirikizumab - moderately to severely active ulcerative colitis (NICE TA925)

Baricitinib - severe alopecia areata (NICE TA926)

The following Items will be updated and added to the website following the next Clinical Effectivness Group (CEG) Meeting:

Empagliflozin - chronic kidney disease (NICE TA942)